To further understand whether the androgen receptor inhibitor may be attributable to cell cycle changes, we used flow cytometry to evaluate the effect of enzalutamide alone and in combination with ribociclib on the cell cycle profile of breast cancer cell lines. Here, AR is linked to breast carcinoma.